Metabolic, Bariatric Surgery, GLP-1 Receptor Agonist Therapy Both Reduce ASCVD Risk

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on May 11, 2026.

via HealthDay

MONDAY, May 11, 2026 -- For adults with obesity, both metabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy are associated with reductions in 10-year atherosclerotic cardiovascular disease (ASCVD) risk, but lifetime ASCVD risk decreases more following MBS, according to a study published online April 20 in the Annals of Surgery.

Wissam Ghusn, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues compared one-year changes in estimated 10-year and lifetime ASCVD risk following MBS versus GLP-1 RA therapy among adults with obesity in a retrospective cohort study. The cohort included 812 patients: 579 underwent MBS and 233 initiated GLP-1 RA therapy.

The researchers found that patients receiving GLP-1 RA therapy were older at baseline and had higher estimated ASCVD risk. At one year, similar reductions in 10-year ASCVD risk were seen (−0.8 percent in the MBS group and −1.1 percent in GLP-1 RA group). In contrast, there was a significantly greater decrease seen in lifetime ASCVD risk following MBS versus GLP-1 RA therapy (−8.6 versus −1.7 percent). In addition, greater percent total body weight loss was seen in association with MBS (−27.8 versus −11.1 percent), and lipid changes were more favorable, including larger reductions in low-density lipoprotein cholesterol and greater increases in high-density lipoprotein cholesterol. Compared with GLP-1 RA therapy, MBS remained independently associated with a greater reduction in ASCVD risk after adjustment (β = −6.92).

"Both treatments are effective, but surgery appears to provide a greater reduction in long-term cardiovascular risk, especially when it leads to larger and more sustained weight loss," Ghusn said in a statement.

Several authors disclosed ties to the biopharmaceutical and nutrition industries.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-12 02:42

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords